MARKET

RIGL

RIGL

Rigel Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

2.010
-0.110
-5.19%
After Hours: 2.010 0 0.00% 17:59 05/20 EDT
OPEN
2.150
PREV CLOSE
2.120
HIGH
2.185
LOW
1.970
VOLUME
1.92M
TURNOVER
0
52 WEEK HIGH
4.620
52 WEEK LOW
1.800
MARKET CAP
345.82M
P/E (TTM)
-4.0532
1D
5D
1M
3M
1Y
5Y
Recap: Rigel Pharmaceuticals Q1 Earnings
Rigel Pharmaceuticals (NASDAQ:RIGL) reported its Q1 earnings results on Tuesday, May 3, 2022 at 04:01 PM. Here's what investors need to know about the announcement.
Benzinga · 05/03 21:36
Rigel Pharmaceuticals (RIGL) Reports Q1 Loss, Misses Revenue Estimates
Rigel (RIGL) delivered earnings and revenue surprises of -33.33% and 9.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/03 21:35
BRIEF-Rigel Reports First Quarter 2022 Financial Results
reuters.com · 05/03 20:44
Rigel Pharmaceuticals Q1 EPS $(0.16) Misses $(0.14) Estimate, Sales $16.70M Miss $17.54M Estimate
Rigel Pharmaceuticals (NASDAQ:RIGL) reported quarterly losses of $(0.16) per share which missed the analyst consensus estimate of $(0.14) by 14.29 percent. This is a 172.73 percent decrease over earnings of $0.22 per
Benzinga · 05/03 20:18
Rigel Pharmaceuticals GAAP EPS of -$0.16 misses by $0.02, revenue of $16.74M misses by $0.8M
Rigel Pharmaceuticals press release (NASDAQ:RIGL): Q1 GAAP EPS of -$0.16 misses by $0.02. Revenue of $16.74M (-79.3% Y/Y) misses by $0.8M. As of March 31, 2022, Rigel had cash, cash
Seekingalpha · 05/03 20:12
-- Earnings Flash (RIGL) RIGEL PHARMACEUTICALS Posts Q1 Loss $-0.16, vs. Street Est of $-0.14
MT Newswires · 05/03 16:04
The Daily Biotech Pulse: FDA's AdComm For Acadia's Pimavanserin, Review Issues For Spero's Tebipenem Application, Cortexyme Layoffs
Here's a roundup of top developments in the biotech space over the last 24 hours.
Benzinga · 05/03 13:01
Notable earnings after Tuesday's close
ABNB, ACHC, ADC, AHT, AIG, AIZ, AKAM, ALR, AMCR, AMD, ANDE, APPH, AQST, ATEN, AYX, BFAM, BGFV, BLKB, BNFT, BNL, BTG, BXC, CGBD, CHCT, CNDT, CNR, COKE, CRK, CRUS, CTSO,
Seekingalpha · 05/02 21:35
More
No Data
Learn about the latest financial forecast of RIGL. Analyze the recent business situations of Rigel Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

28.57%Strong Buy
57.14%Buy
14.29%Hold
0.00%Under-perform
0.00%Sell
Analyst Price Target
The average RIGL stock price target is 7.14 with a high estimate of 11.00 and a low estimate of 4.000.
High11.00
Average7.14
Low4.000
Current 2.010
EPS
Actual
Estimate
-0.13-0.10-0.06-0.03
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Institutional Holdings
Institutions: 223
Institutional Holdings: 158.79M
% Owned: 92.29%
Shares Outstanding: 172.05M
TypeInstitutionsShares
Increased
43
10.58M
New
27
3.64M
Decreased
56
8.23M
Sold Out
25
5.47M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.65%
Pharmaceuticals & Medical Research
+1.64%
Key Executives
Non-Executive Chairman/Independent Director
Gary Lyons
President/Chief Executive Officer/Director
Raul Rodriguez
Chief Financial Officer/Executive Vice President
Dean Schorno
Executive Vice President/General Counsel/Secretary
Dolly Vance
Executive Vice President
Wolfgang Dummer
Executive Vice President
David Santos
Independent Director
Kamil Ali-Jackson
Independent Director
Bradford Goodwin
Independent Director
Alison Hannah
Independent Director
Keith Katkin
Independent Director
Brian Kotzin
Independent Director
Gregg Lapointe
Independent Director
Walter Moos
Independent Director
Jane Wasman
No Data
No Data
About RIGL
Rigel Pharmaceuticals, Inc. is a biotechnology company. The Company is engaged in discovering, developing and providing small molecule drugs that improve the lives of patients with hematologic disorders, cancer and rare immune diseases. The Company's research focuses on signaling pathways that are critical to disease mechanisms. The Company's product, TAVALISSE (fostamatinib disodium hexahydrate) tablets, the oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia (ITP). Its clinical program, Fostamatinib is being studied in a Phase III trial for the treatment of warm autoimmune hemolytic anemia (wAIHA). The Company's other clinical programs include its interleukin receptor-associated kinase (IRAK) inhibitor program and a receptor-interacting serine/threonine-protein kinase (RIP1) inhibitor program.

Webull offers kinds of Rigel Pharmaceuticals, Inc. stock information, including NASDAQ:RIGL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RIGL stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading RIGL stock methods without spending real money on the virtual paper trading platform.